Javascript was detected to be disabled. Javascript is required for some functions on this website.

The Institute for Innovation & Valuation in Health Care, InnoValHC, is an independent not-for-profit research organization. It was established by scientists with medical, health economic, and econometric backgrounds, as well as hands-on management experience, to analyse health economic and treatment strategies (see Profile). Learn more about the institute's Purpose and Projects.

News

Interventions for Ultra-Rare Disorders (URDs): How to Assess “Value for Money”?

Now available for download:

The “URD Consensus” documented as a peer-reviewed publication in the Journal of Market Access and Health Policy.

Read more …

Recent Scientific Presentations at the 19th Annual European ISPOR Congress in Vienna / Austria, October 29 – November 03, 2016

Now available for download:

Abstracts and presentations on “Comparing HTAs in Germany and UK”, “Budget Impact and Cost Drivers of Drugs for Rare and Ultra-Rare Diseases in Europe”, and key design elements of the SoPHI [Social Preferences for Health Interventions) Study (“European Social Preference Measurement [ESPM] Project”)

Read more …

Invitation to Stakeholders concerned with Economic Evaluation and Health Technology Assessments (HTAs)

Announcement: Heidelberg Health Economics Summer School 2016

Dear Colleague:

Following the positive feedback we received regarding last year’s Health Economics Summer School, we decided to offer a new program in 2016.

Read more …

Heidelberg Health Economics Summer School 2016

A program offered by InnoValHC in cooperation with the University of Heidelberg,
Mannheim Institute of Public Health (Mannheim Medical Faculty),

September 19-21, 2016: Essential Modeling Techniques for Cost Effectiveness Analysis (Workshop)
September 26-28, 2016: Health Care Payers’ & Policy Makers’ Forum (Current & Future Expectations)

The number of participants will be limited to facilitate an intense exchange with faculty, presenters, and colleagues. We therefore recommend early registration. For more information, please contact us at academy(at)innoval-hc.com.

Read more …

The Social Value of Orphan Medicinal Products

Now online available: First public presentation and discussion of the European Social Preference Measurement (ESPM) project at the Multi-Stakeholder Symposium on improving patient access to rare disease therapies, organized by “Rare Diseases Europe” (EURORDIS) in Brussels, February 24, 2016.

Read more …